KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Change in Cash (2016 - 2025)

Historic Change in Cash for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to -$301.0 million.

  • Pfizer's Change in Cash rose 8294.62% to -$301.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.5 billion, marking a year-over-year increase of 6185.81%. This contributed to the annual value of -$1.8 billion for FY2024, which is 17393.79% down from last year.
  • Pfizer's Change in Cash amounted to -$301.0 million in Q3 2025, which was up 8294.62% from $213.0 million recorded in Q2 2025.
  • Over the past 5 years, Pfizer's Change in Cash peaked at $1.8 billion during Q2 2023, and registered a low of -$2.1 billion during Q1 2024.
  • Moreover, its 5-year median value for Change in Cash was $211.0 million (2021), whereas its average is -$51.7 million.
  • As far as peak fluctuations go, Pfizer's Change in Cash skyrocketed by 362666.67% in 2022, and later plummeted by 42990.65% in 2024.
  • Over the past 5 years, Pfizer's Change in Cash (Quarter) stood at $209.0 million in 2021, then crashed by 409.09% to -$646.0 million in 2022, then surged by 51.08% to -$316.0 million in 2023, then crashed by 458.54% to -$1.8 billion in 2024, then skyrocketed by 82.95% to -$301.0 million in 2025.
  • Its Change in Cash stands at -$301.0 million for Q3 2025, versus $213.0 million for Q2 2025 and $375.0 million for Q1 2025.